Precision treatment for severe asthma targets a specific mutation

(Boston Children's Hospital) Under a $10 million NIH grant, a randomized, placebo-controlled clinical trial led by Boston Children's Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable. The four-center trial follows a half-decade of research at the hospital showing how a mutation in the gene ILR4 causes severe, hard-to-treat asthma -- and the potential for an existing drug to counter it.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news